29
Participants
Start Date
February 21, 2023
Primary Completion Date
March 13, 2025
Study Completion Date
March 13, 2025
STAR-0215
STAR-0215 will be administered as a subcutaneous bolus injection.
Diagnostical Consultative Center Convex Ltd., Sofia
Charité Universitätsmedizin Berlin, Berlin
Penn State Health Milton S. Hershey Medical Center, Hershey
Institute for Asthma and Allergy, PC, Chevy Chase
Allervie Clinical Research, Birmingham
Optimed Research, Columbus
Washington University School of Medicine, St Louis
Acuro Research, Inc., Little Rock
Allergy & Asthma Clinic of Northwest Arkansas, Bentonville
AARA Research Center, Dallas
Medical Research of Arizona a Division of Allergy, Asthma & Immunology Associates, LTD., Scottsdale
Raffi Tachdjian MD, Inc, Santa Monica
UC San Diego US HAEA Angioedema Center, San Diego
Allergy & Asthma Clinical Research, Walnut Creek
Massachusetts General Hospital, Boston
University of Alberta, Edmonton
Ottawa Allergy Research Corporation, Ottawa
Institute of Clinical Immunology/Allergology, Faculty Hospital, Hradec Králové
Addenbrooke's Hospital, Cambridge
St. James's Hospital, Leeds
Lead Sponsor
Astria Therapeutics, Inc.
INDUSTRY